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A Study of Magnetic Drug Delivery System Using
Bulk High Temperature Superconducting Magnet
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Hiroshi Iseki, Yoshihiro Muragaki, Akira Sasaki, Kubota Jun, and Norihide Saho
Abstract—A magnetic drug delivery system (MDDS) has been
studied to navigate and/or accumulate the magnetic seeded drug
at a local diseased part in the human body. The bulk high temper-
ature superconductors (HTS) are employed to control the drug be-
cause they would produce the required magnetic fields for MDDS.
The trajectory of the ferromagnetic particles in the blood vessel
was calculated and the possibility of the navigation of the drug is
discussed. In the experiment the HTS (GdBaCuO) which produces
the magnetic field of 4.5 T at the surface, was located 25 mm apart
from the Y-shaped blood vessel. The drug navigation probability
to the desired direction was confirmed to be higher than 80%. A
rat experiment was also performed successfully using a permanent
magnet. The possible MDDS system will be discussed.
Index Terms—Bulk high temperature superconductor, magnetic
drug delivery system, magnetic seeded drug, nano-sized particle,
navigation of drag.
I. INTRODUCTION
WHEN the drug delivery system that accurately transportsthe drug of the proper quantity to the diseased part is
used, the reduction of the dosage and the side effect can be
expected more than the conventional administering technique.
Moreover, it is thought that the treatment of a difficult part of a
surgical approach becomes possible, and an effective treatment
method to an obstinacy disease is achieved. We decided to apply
the technique of the particle motion control by magnetic force
to the DDS [1]–[3].
Magnetic force to the magnetic seeded drug with the fer-
romagnetic fine particle is induced by a superconducting bulk
magnet. The magnet is placed outside of the body. The magnetic
seeded drug is injected into a blood vessel and is navigated to
the diseased part by the magnetic force. The applicability of the
MDDS has been studied [4], [5].
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Fig. 1. Course that sends a drug to a diseased part in MDDS.
Because the drug can be controlled by the magnetic force in
the body, the achievement of a high concentration of the drug
in a target diseased part. The reduction of toxicity to the normal
tissue with the drug could be achieved and hence MDDS is one
of promising DDS. In this work the possibility of MDDS was
examined. The animal test [6] was also performed using rat.
II. CONCEPT OF MDDS
The following methods were devised as a method of MDDS.
The drug is conveyed by the current of blood and is delivered.
The magnet is put on the surface of the body near the branching
point of the blood vessel. The drug is delivered in the direction of
the purpose by the magnetic force. The drug is finally delivered
to a targeted diseased part by repeating this navigation.
When this concept is actually used, the following procedure
will be made. First, the magnetic seeded drug is introduced into
the inside of the body by the vein injection. The drug goes from
the vein to the heart (right atrium), passed pulmonary artery
from the right ventricle, and circulates to lungs, the pulmonary
vein, and the heart (left atrium). Then blood spreads in the whole
body from the left ventricle through the aorta as shown in Fig. 1.
The magnetic seeded drug that has come out from the left ven-
tricle is navigated in a specific direction with the supercon-
ducting magnet placed outside of the body near the branching
point of the blood vessel. This navigation is repeated two or
more times. Moreover, the magnet is placed in the diseased part
and hence the drug is accumulated at the diseased part by the
magnetic force [7]–[9]. To pass the capillary of lungs and to
1051-8223/$25.00 © 2008 IEEE
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Fig. 2. Effect of the branching point on the drug concentration in the diseased
part with navigation rate of 2:1.
prevent the phagocytosis, a drug of 100 nm or less is said to be
preferable.
The necessary navigation efficiency was calculated. The
concentration of the drug in blood after navigation is shown
schematically in Fig. 2. It is assumed that the diseased part
exists after branching two times of blood vessel. When the drug
concentration in blood before branching is assumed to be 4a,
the concentration after two times branching becomes a. Hence,
the concentration of the drug in the diseased part is a.
When the navigation rate is set to 2:1 at the 2nd branching
point, the ratio of drug concentration in blood is 1.33a:0.66a
after the 2nd branching. The improvement of the concentration
of the drug in the diseased part is about 33%.
When the navigation rate is set to 2:1 at the 1st branching
point, the ratio of drug concentration in blood is 2.66a:1.33a
after the first branching. After 2nd branching the concentration
of the drug becomes 1.33a or 0.66a. It means that the blood
having 33% increase of drug concentration is admitted in the
diseased part.
When the navigation ratio is adjusted to 2:1 upstream of the
diseased part, the concentration of the drug is increased by 33%
in the diseased part. In practical use of MDDS the 30% improve-
ment of the drug concentration can be expected in the diseased
part if the navigation ratio is set 2:1 upstream of the diseased
part, where the navigation is easily made (that is the blood vessel
near the body surface or vessel density is a little). When the nav-
igation efficiency is adjusted to 4:1, a concentration increase of
about 60% will be admitted. The tentative target of this research
was assumed to adjust the navigation ratio 2:1 or more.
III. NAVIGATION WITH BULK SUPERCONDUCTING MAGNET
The following 2 subjects were examined in the study.
1) Using magnetite particle of 100 nm in the diameter, pos-
sibility of the navigation rate of 2:1 is examined with water
of 200 mm/s in a glass tube placed away from the magnet by
50 mm. 2) Using 100 nm magnetite particle, the possibility of
the navigation rate of 2:1 is examined with blood of 200 mm/s
in a blood vessel placed away from the magnet by 25 mm.
Since there were a lot of discussions about the magnetic navi-
gation of nano-sized particle, to clarify the condition that is able
Fig. 3. Magnetic field generated by a bulk superconducting magnet.
to be navigated quantitatively, the calculation and the experi-
ment were made.
A. Particle Trajectory in Magnetic Field
A calculation was made to see if the required magnetic fields
can be generated by the bulk superconducting at deep inside of
body. The flow velocity distribution in the glass tube and the
magnetic field distribution around the magnet were analyzed by
using finite element method (FEM). Then the particle trajectory
in the magnetic field was calculated by using the results of FEM.
The particle trajectories are calculated according to the fol-
lowing procedures.
Water was thrown into the straight glass tube of 2 mm in
the inner diameter at the speed of 200 mm/s. Several magnetite
particles of which the diameter is 100 nm were put in this. As
an initial condition, the speed of the particle was set as the drag
force to the particle becomes 0. Magnetic force and drag




Here, and are volume magnetic susceptibility of the
particle and the fluid. The , and are the speeds of the par-
ticle and the fluid, respectively. The is the viscosity of the fluid,
the particle diameter, strength of the magnetic field. As the
difference between and is the force to the particle, the
equation of motion of the particle was solved with time evolu-
tion. The viscosity of water were assumed to be .
In the calculation up to 0.5 T the intensity of magnetization was
proportional to magnetic field (the volume magnetic suscepti-
bility was 8000), and then came to be constant as saturated mag-
netization (0.6 T).
Fig. 3 shows the contour line of the magnetic field generated
by the bulk superconducting magnet. A disk shaped balk su-
perconductor of which dimension was 40 mm in diameter and
15 mm in thickness was used in the calculation assuming the
critical current density as A/m . The magnetic flux den-
sity at the surface of the magnet was 4.5 T. The critical cur-
rent density was set to reproduce the measured magnetic flux
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Fig. 4. Trajectories of the particle in a glass tube put to the distance of 40 mm.
Fig. 5. A change of the accumulation rate with the distance.
density. The particle trajectories of the ferromagnetic particles
in water were calculated in the magnetic filed generated by the
bulk superconducting magnet.
Fig. 4 shows calculated results of particle trajectories. The
glass tube was located at 40 mm above the bulk supercon-
ducting magnet. It was understood that even at the distance of
40 mm above the magnet the particles can be accumulated. The
accumulated fraction was calculated by changing the distance
between glass tube and the magnet assuming the parabolic
flow velocity distribution and shown in Fig. 5. This suggests
that the particle can be accumulated up to 50 mm distance. In
the blood the higher magnetic field would be necessary for the
accumulation.
B. Navigation From a Long Distance
Based on the calculation, the navigation experiments were
made in water 50 mm away and in blood 25 mm away from the
magnet. The blood and blood vessel taken from pigs were used.
The branching point of glass tube or blood vessel was placed
above 50 mm or 25 mm from the surface of the bulk magnet.
The distilled water was thrown at the flow velocity of
200 mm/s in the Y-shaped glass tube of which inside diameter
is 2 mm. The branching point of glass tube was placed above
50 mm from the surface of the bulk magnet. The suspension
was injected into the tube before the branching point and the
navigation efficiency after branching was measured.
For preparing the suspension the magnetite particle of 100 nm
in diameter was dispersed in water. The particle size distribu-
tion was measured to see if the particle aggregate or not. The
dispersed particle was confirmed not to aggregate in water.
The magnetic flux density of the bulk superconducting
magnet used for the navigation is 4.5 T on the surface of
Fig. 6. Appearance of the experimental set up.
Fig. 7. Schematic view of the navigation at branching point by a bulk super-
conducting magnet.
the magnet. A magnetic field and a magnetic gradient at the
Y-shaped glass tube were 0.088 T and 4.3 T/m, respectively.
The navigation efficiency was measured with a magnetic bal-
ance. The photograph of the experimental set up is shown in
Fig. 6. The ferromagnetic particle was navigated to downward
in the experiment. It was examined whether the navigation rate
can be more than 2:1.
It was successfully confirmed that the navigation rate was
66.9:33.1.
The navigation experiment was made by using the blood of
pig and the branching point of blood vessel in abdominal aorta
of pig. The bulk superconducting magnet was also used as a
magnetic field source. The schematic illustration of the experi-
mental set up was shown in Fig. 7. The blood vessel was kept
horizontally and parallel to the surface of the magnet, and was
placed at 25 mm distance from the magnet. The blood was
thrown in the blood vessel at the speed of 200 mm/s. The mag-
netite suspension was injected to the blood stream at the speed
of 3 ml/min. The magnetic field and the gradient of the magnetic
field at the branching point were 0.3 T and 25 T/m, respectively.
Two blood vessels that were used are 4 mm and 3 mm in inner
diameter. The obtained navigation rate was 86.9:13.1 (6.6:1) in
4 mm and 89.9:10.1 (8.9:1) in 3 mm blood vessel. In Fig. 8 the
photos of Y-shaped blood vessel were shown.
It was confirmed by means of calculation and experiment that
with the bulk superconducting magnet the navigation rate can
attain 2:1 even at deep inside of the body.
IV. ANIMAL EXPERIMENT
The animal experiment using rat was performed. As a
Y-shaped blood vessel the abdominal aorta branching to right
and left ileum artery was chosen. A permanent magnet of which
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Fig. 8. Y-shaped blood vessel and navigation at branching point.
Fig. 9. Navigation experiment at branching point of blood vessel using rat and
permanent magnet.
magnetic field was 0.3 T was put near the right ileum after
branching. Magnetic capsules were injected into the abdominal
aorta and the quantity of the capsules guided by a magnetic
field was measured with a magnetic balance. In Fig. 9 the
experimental method was shown. The concentration of the cap-
sules was compared between the blood vessel with the magnet
and the one without the magnet. The magnet increased the
concentration of the capsule more than double. The navigation
ratio was found to be 86.0:14.0.
V. HEAD CERVICAL CANCER
An advantageous part for a clinical application of MDDS was
surveyed based on the obtained results. It was proposed that
MDDS could be applied to skin cancer, bone tumors and head
cervical cancer (nose, mouth, jaw, throat and ear), lung cancer,
and liver cancer. Especially, high navigation efficiency can be
expected to the skin cancer. Concerning lung cancer, as there are
no surrounding internal organs, the local drug concentration can
be increases by MDDS and hence MDDS could be a promising
treatment method.
It was also pointed out that there was a possibility of be-
coming a treatment method that took the place of the artery in-
jection chemotherapy about the head cervical cancer.
VI. CONCLUSION
The concept of MDDS and the method to realize were exam-
ined. In the method the magnetic seeded drug was introduced
into the inside of the body by the vein injection and navigated
at the branching point of the artery to the diseased part. When
the navigation efficiency was increased to 2:1 in the branching
point, the concentration of the drug was shown to be improved
by 30% in the downstream. The calculation method for the nav-
igation of the magnetic seeded drug in the blood vessel by the
magnetic field was developed. The calculation showed that the
bulk superconducting magnet was possible to obtain the naviga-
tion efficiency of 2:1 at deep inside of the body of 50 mm. The
calculation result was actually confirmed by the experiment.
The animal experiment was also performed successfully. The
clinical applications with high possibility were surveyed based
on the obtained results.
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